Pneumonia Vaccine Market is expected to reach US$ 13.31 Bn. at a CAGR of 5 during the forecast period 2029. Pneumococcal disease caused by streptococcus pneumonia is the prominent cause of pneumonia, which results in the greatest number of deaths in children under five years of age globally. The WHO recommends that pneumococcal vaccines be introduced into all national immunisation programs, particularly in economies with high child mortality.To know about the Research Methodology :- Request Free Sample Report The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. The report covers all the trends and technologies playing a major role in the growth of the pneumonia vaccine market over the forecast period. It highlights the drivers, restraints, and opportunities expected to influence market growth during 2021-2029. As pharmaceutical companies are being reluctant to invest in production of new vaccines because of very fewer returns, vendors are opting advanced market commitment (AMC), an innovative financing program under which international agencies pay a premium above the incremental production cost for initial doses sold to emerging economies and in exchange, vendors agree to continue supply of vaccines at sustainable costs for long term. Based on the vaccine type, 13-valent PCV vaccine segment is expected to account for the largest xx% market share by 2029. PVC13 provides a significant benefit for preventing pneumonia and invasive diseases caused by Streptococcus pneumonia in adults and children. The CDC (Centers for Disease Control and Prevention) PCV13 vaccines for children below 2 and adults above 65 years of age. Additionally, it is now recommended that adults above 65 and older to get both PCV13 and PPSV23 vaccine for better immunogenicity against many serotypes of pneumococcus. The report offers a brief analysis of the major regions in the pneumonia vaccine market, namely, APAC, Europe, North America, Latin America, and the Middle East & Africa. North America held the largest xx% share in the pneumococcal vaccines market in 2017. Growing government funding and awareness programs in the region are fueling the market. Such as, PCV has been introduced in the routine immunization program to curb the burden of pneumococcus diseases. The competitive landscape section in the pneumonia vaccine market proposals a deep dive into the profiles of the leading companies operating in the global market landscape. It offers captivating insights on the key developments, differential strategies, and other crucial aspects about the key players having a stronghold in the pneumonia vaccine market. In January 2018, Pfizer reduced the price of its PCV-13 4 dose vial vaccine for GAVI-supported countries from $3.05 to $2.95 per dose. Growing addition of pneumococcal vaccine in national immunization programs is favoring the growth of pneumococcal vaccines market. According to the World Health Organization (WHO) until 2017, a total of 138 economies are introduced with pneumococcal vaccines in their national immunization program. The objective of the report is to present comprehensive analysis of Global Pneumonia Vaccine Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Global Pneumonia Vaccine Market dynamics, structure by analyzing the market segments, and project the Global Pneumonia Vaccine Market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Pneumonia Vaccine Market make the report investor’s guide.
Scope of the Global Pneumonia Vaccine Market: Inquire before buying
Global Pneumonia Vaccine Market Report Coverage Details Base Year: 2021 Forecast Period: 2022-2029 Historical Data: 2017 to 2021 Market Size in 2021: US $ 9.01Bn. Forecast Period 2022 to 2029 CAGR: 5% Market Size in 2029: US $ 13.31 Bn. Segments Covered: by Vaccine Type • Pneumococcal Conjugate Vaccine • Pneumococcal Polysaccharide Vaccine by Product Type • Prevnar 13 • Synflorix • Pneumovax 23 by Sector • Public • Private by Distribution Channel •Distribution Partner Companies • Non-governmental Organizations (NGO) • Government Authorities Pneumonia Vaccine Market, by Region
• North America • Asia Pacific • Europe • Middle East & Africa • South AmericaPneumonia Vaccine Market Key Players are:
• Bayer AG • GlaxoSmithKline plc • Pfizer Inc. • Nuron Biotech Inc. • CSL Ltd. • Biomed Pvt. Ltd. • Serum Institute of India Pvt. Ltd. • Sanofi Pasteur Inc. • JN-International Medical Corporation • Merck & Co., Inc. • LG Chem Ltd. • Panacea Biotec Limited • Pnuvax Incorporated • Shenzhen Kangtai Biological Products Co., Ltd. • SK Bioscience • Walvax Biotechnology Co., Ltd.Frequently Asked questions
1. What is the market size of the Global Pneumonia Vaccine Market in 2021? Ans. The market size Global Pneumonia Vaccine Market in 2021 was US$ 9.01 Billion. 2. What are the different segments of the Global Pneumonia Vaccine Market? Ans. The Global Pneumonia Vaccine Market is divided into Sector, Product, Vaccine Type and Distribution Channel. 3. What is the study period of this market? Ans. The Global Pneumonia Vaccine Market will be studied from 2021 to 2029. 4. Which region is expected to hold the highest Global Pneumonia Vaccine Market share? Ans. The Asia Pacific dominates the market share in the market. 5. What is the Forecast Period of Global Pneumonia Vaccine Market? Ans. The Forecast Period of the market is 2022-2029 in the market.
Global Pneumonia Vaccine Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Pneumonia Vaccine Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Pneumonia Vaccine Market Analysis and Forecast 6.1. Global Pneumonia Vaccine Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Pneumonia Vaccine Market Analysis and Forecast, By Vaccine Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Pneumonia Vaccine Market Value Share Analysis, By Vaccine Type 7.4. Global Pneumonia Vaccine Market Size (US$ Bn) Forecast, By Vaccine Type 7.5. Global Pneumonia Vaccine Market Analysis, By Vaccine Type 7.6. Global Pneumonia Vaccine Market Attractiveness Analysis, By Vaccine Type 8. Global Pneumonia Vaccine Market Analysis and Forecast, By Sector 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Pneumonia Vaccine Market Value Share Analysis, By Sector 8.4. Global Pneumonia Vaccine Market Size (US$ Bn) Forecast, By Sector 8.5. Global Pneumonia Vaccine Market Analysis, By Sector 8.6. Global Pneumonia Vaccine Market Attractiveness Analysis, By Sector 9. Global Pneumonia Vaccine Market Analysis and Forecast, By Product Type 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Pneumonia Vaccine Market Value Share Analysis, By Product Type 9.4. Global Pneumonia Vaccine Market Size (US$ Bn) Forecast, By Product Type 9.5. Global Pneumonia Vaccine Market Analysis, By Product Type 9.6. Global Pneumonia Vaccine Market Attractiveness Analysis, By Product Type 10. Global Pneumonia Vaccine Market Analysis and Forecast, By Distribution Channel 10.1. Introduction and Definition 10.2. Key Findings 10.3. Global Pneumonia Vaccine Market Value Share Analysis, By Distribution Channel 10.4. Global Pneumonia Vaccine Market Size (US$ Bn) Forecast, By Distribution Channel 10.5. Global Pneumonia Vaccine Market Analysis, By Distribution Channel 10.6. Global Pneumonia Vaccine Market Attractiveness Analysis, By Distribution Channel 11. Global Pneumonia Vaccine Market Analysis, by Region 11.1. Global Pneumonia Vaccine Market Value Share Analysis, by Region 11.2. Global Pneumonia Vaccine Market Size (US$ Bn) Forecast, by Region 11.3. Global Pneumonia Vaccine Market Attractiveness Analysis, by Region 12. North America Pneumonia Vaccine Market Analysis 12.1. Key Findings 12.2. North America Pneumonia Vaccine Market Overview 12.3. North America Pneumonia Vaccine Market Value Share Analysis, By Vaccine Type 12.4. North America Pneumonia Vaccine Market Forecast, By Vaccine Type 12.4.1. Pneumococcal Conjugate Vaccine 12.4.2. Pneumococcal Polysaccharide Vaccine 12.5. North America Pneumonia Vaccine Market Value Share Analysis, By Sector 12.6. North America Pneumonia Vaccine Market Forecast, By Sector 12.6.1. Public 12.6.2. Private 12.7. North America Pneumonia Vaccine Market Value Share Analysis, By Product Type 12.8. North America Pneumonia Vaccine Market Forecast, By Product Type 12.8.1. Prevnar 13 12.8.2. Synflorix 12.8.3. Pneumovax 23 12.9. North America Pneumonia Vaccine Market Value Share Analysis, By Distribution Channel 12.10. North America Pneumonia Vaccine Market Forecast, By Distribution Channel 12.10.1. Distribution Partner Companies 12.10.2. Non-governmental Organizations (NGO) 12.10.3. Government Authorities 12.11. North America Pneumonia Vaccine Market Value Share Analysis, by Country 12.12. North America Pneumonia Vaccine Market Forecast, by Country 12.12.1. U.S. 12.12.2. Canada 12.13. North America Pneumonia Vaccine Market Analysis, by Country 12.14. U.S. Pneumonia Vaccine Market Forecast, By Vaccine Type 12.14.1. Pneumococcal Conjugate Vaccine 12.14.2. Pneumococcal Polysaccharide Vaccine 12.15. U.S. Pneumonia Vaccine Market Forecast, By Sector 12.15.1. Public 12.15.2. Private 12.16. U.S. Pneumonia Vaccine Market Forecast, By Product Type 12.16.1. Prevnar 13 12.16.2. Synflorix 12.16.3. Pneumovax 23 12.17. U.S. Pneumonia Vaccine Market Forecast, By Distribution Channel 12.17.1. Distribution Partner Companies 12.17.2. Non-governmental Organizations (NGO) 12.17.3. Government Authorities 12.18. Canada Pneumonia Vaccine Market Forecast, By Vaccine Type 12.18.1. Pneumococcal Conjugate Vaccine 12.18.2. Pneumococcal Polysaccharide Vaccine 12.19. Canada Pneumonia Vaccine Market Forecast, By Sector 12.19.1. Public 12.19.2. Private 12.20. Canada Pneumonia Vaccine Market Forecast, By Product Type 12.20.1. Prevnar 13 12.20.2. Synflorix 12.20.3. Pneumovax 23 12.21. Canada Pneumonia Vaccine Market Forecast, By Distribution Channel 12.21.1. Distribution Partner Companies 12.21.2. Non-governmental Organizations (NGO) 12.21.3. Government Authorities 12.22. North America Pneumonia Vaccine Market Attractiveness Analysis 12.22.1. By Vaccine Type 12.22.2. By Sector 12.22.3. By Product Type 12.22.4. By Distribution Channel 12.23. PEST Analysis 12.24. Key Trends 12.25. Key Developments 13. Europe Pneumonia Vaccine Market Analysis 13.1. Key Findings 13.2. Europe Pneumonia Vaccine Market Overview 13.3. Europe Pneumonia Vaccine Market Value Share Analysis, By Vaccine Type 13.4. Europe Pneumonia Vaccine Market Forecast, By Vaccine Type 13.4.1. Pneumococcal Conjugate Vaccine 13.4.2. Pneumococcal Polysaccharide Vaccine 13.5. Europe Pneumonia Vaccine Market Value Share Analysis, By Sector 13.6. Europe Pneumonia Vaccine Market Forecast, By Sector 13.6.1. Public 13.6.2. Private 13.7. Europe Pneumonia Vaccine Market Value Share Analysis, By Product Type 13.8. Europe Pneumonia Vaccine Market Forecast, By Product Type 13.8.1. Prevnar 13 13.8.2. Synflorix 13.8.3. Pneumovax 23 13.9. Europe Pneumonia Vaccine Market Value Share Analysis, By Distribution Channel 13.10. Europe Pneumonia Vaccine Market Forecast, By Distribution Channel 13.10.1. Distribution Partner Companies 13.10.2. Non-governmental Organizations (NGO) 13.10.3. Government Authorities 13.11. Europe Pneumonia Vaccine Market Value Share Analysis, by Country 13.12. Europe Pneumonia Vaccine Market Forecast, by Country 13.12.1. Germany 13.12.2. U.K. 13.12.3. France 13.12.4. Italy 13.12.5. Spain 13.12.6. Rest of Europe 13.13. Europe Pneumonia Vaccine Market Analysis, by Country 13.14. Germany Pneumonia Vaccine Market Forecast, By Vaccine Type 13.14.1. Pneumococcal Conjugate Vaccine 13.14.2. Pneumococcal Polysaccharide Vaccine 13.15. Germany Pneumonia Vaccine Market Forecast, By Sector 13.15.1. Public 13.15.2. Private 13.16. Germany Pneumonia Vaccine Market Forecast, By Product Type 13.16.1. Prevnar 13 13.16.2. Synflorix 13.16.3. Pneumovax 23 13.17. Germany Pneumonia Vaccine Market Forecast, By Distribution Channel 13.17.1. Distribution Partner Companies 13.17.2. Non-governmental Organizations (NGO) 13.17.3. Government Authorities 13.18. U.K. Pneumonia Vaccine Market Forecast, By Vaccine Type 13.18.1. Pneumococcal Conjugate Vaccine 13.18.2. Pneumococcal Polysaccharide Vaccine 13.19. U.K. Pneumonia Vaccine Market Forecast, By Sector 13.19.1. Public 13.19.2. Private 13.20. U.K. Pneumonia Vaccine Market Forecast, By Product Type 13.20.1. Prevnar 13 13.20.2. Synflorix 13.20.3. Pneumovax 23 13.21. U.K. Pneumonia Vaccine Market Forecast, By Distribution Channel 13.21.1. Distribution Partner Companies 13.21.2. Non-governmental Organizations (NGO) 13.21.3. Government Authorities 13.22. France Pneumonia Vaccine Market Forecast, By Vaccine Type 13.22.1. Pneumococcal Conjugate Vaccine 13.22.2. Pneumococcal Polysaccharide Vaccine 13.23. France Pneumonia Vaccine Market Forecast, By Sector 13.23.1. Public 13.23.2. Private 13.24. France Pneumonia Vaccine Market Forecast, By Product Type 13.24.1. Prevnar 13 13.24.2. Synflorix 13.24.3. Pneumovax 23 13.25. France Pneumonia Vaccine Market Forecast, By Distribution Channel 13.25.1. Distribution Partner Companies 13.25.2. Non-governmental Organizations (NGO) 13.25.3. Government Authorities 13.26. Italy Pneumonia Vaccine Market Forecast, By Vaccine Type 13.26.1. Pneumococcal Conjugate Vaccine 13.26.2. Pneumococcal Polysaccharide Vaccine 13.27. Italy Pneumonia Vaccine Market Forecast, By Sector 13.27.1. Public 13.27.2. Private 13.28. Italy Pneumonia Vaccine Market Forecast, By Product Type 13.28.1. Prevnar 13 13.28.2. Synflorix 13.28.3. Pneumovax 23 13.29. Italy Pneumonia Vaccine Market Forecast, By Distribution Channel 13.29.1. Distribution Partner Companies 13.29.2. Non-governmental Organizations (NGO) 13.29.3. Government Authorities 13.30. Spain Pneumonia Vaccine Market Forecast, By Vaccine Type 13.30.1. Pneumococcal Conjugate Vaccine 13.30.2. Pneumococcal Polysaccharide Vaccine 13.31. Spain Pneumonia Vaccine Market Forecast, By Sector 13.31.1. Public 13.31.2. Private 13.32. Spain Pneumonia Vaccine Market Forecast, By Product Type 13.32.1. Prevnar 13 13.32.2. Synflorix 13.32.3. Pneumovax 23 13.33. Spain Pneumonia Vaccine Market Forecast, By Distribution Channel 13.33.1. Distribution Partner Companies 13.33.2. Non-governmental Organizations (NGO) 13.33.3. Government Authorities 13.34. Rest of Europe Pneumonia Vaccine Market Forecast, By Vaccine Type 13.34.1. Pneumococcal Conjugate Vaccine 13.34.2. Pneumococcal Polysaccharide Vaccine 13.35. Rest of Europe Pneumonia Vaccine Market Forecast, By Sector 13.35.1. Public 13.35.2. Private 13.36. Rest of Europe Pneumonia Vaccine Market Forecast, By Product Type 13.36.1. Prevnar 13 13.36.2. Synflorix 13.36.3. Pneumovax 23 13.37. Rest Of Europe Pneumonia Vaccine Market Forecast, By Distribution Channel 13.37.1. Distribution Partner Companies 13.37.2. Non-governmental Organizations (NGO) 13.37.3. Government Authorities 13.38. Europe Pneumonia Vaccine Market Attractiveness Analysis 13.38.1. By Vaccine Type 13.38.2. By Sector 13.38.3. By Product Type 13.38.4. By Distribution Channel 13.39. PEST Analysis 13.40. Key Trends 13.41. Key Developments 14. Asia Pacific Pneumonia Vaccine Market Analysis 14.1. Key Findings 14.2. Asia Pacific Pneumonia Vaccine Market Overview 14.3. Asia Pacific Pneumonia Vaccine Market Value Share Analysis, By Vaccine Type 14.4. Asia Pacific Pneumonia Vaccine Market Forecast, By Vaccine Type 14.4.1. Pneumococcal Conjugate Vaccine 14.4.2. Pneumococcal Polysaccharide Vaccine 14.5. Asia Pacific Pneumonia Vaccine Market Value Share Analysis, By Sector 14.6. Asia Pacific Pneumonia Vaccine Market Forecast, By Sector 14.6.1. Public 14.6.2. Private 14.7. Asia Pacific Pneumonia Vaccine Market Value Share Analysis, By Product Type 14.8. Asia Pacific Pneumonia Vaccine Market Forecast, By Product Type 14.8.1. Prevnar 13 14.8.2. Synflorix 14.8.3. Pneumovax 23 14.9. Asia Pacific Pneumonia Vaccine Market Value Share Analysis, By Distribution Channel 14.10. Asia Pacific Pneumonia Vaccine Market Forecast, By Distribution Channel 14.10.1. Distribution Partner Companies 14.10.2. Non-governmental Organizations (NGO) 14.10.3. Government Authorities 14.11. Asia Pacific Pneumonia Vaccine Market Value Share Analysis, by Country 14.12. Asia Pacific Pneumonia Vaccine Market Forecast, by Country 14.12.1. China 14.12.2. India 14.12.3. Japan 14.12.4. ASEAN 14.12.5. Rest of Asia Pacific 14.13. Asia Pacific Pneumonia Vaccine Market Analysis, by Country 14.14. China Pneumonia Vaccine Market Forecast, By Vaccine Type 14.14.1. Pneumococcal Conjugate Vaccine 14.14.2. Pneumococcal Polysaccharide Vaccine 14.15. China Pneumonia Vaccine Market Forecast, By Sector 14.15.1. Public 14.15.2. Private 14.16. China Pneumonia Vaccine Market Forecast, By Product Type 14.16.1. Prevnar 13 14.16.2. Synflorix 14.16.3. Pneumovax 23 14.17. China Pneumonia Vaccine Market Forecast, By Distribution Channel 14.17.1. Distribution Partner Companies 14.17.2. Non-governmental Organizations (NGO) 14.17.3. Government Authorities 14.18. India Pneumonia Vaccine Market Forecast, By Vaccine Type 14.18.1. Pneumococcal Conjugate Vaccine 14.18.2. Pneumococcal Polysaccharide Vaccine 14.19. India Pneumonia Vaccine Market Forecast, By Sector 14.19.1. Public 14.19.2. Private 14.20. India Pneumonia Vaccine Market Forecast, By Product Type 14.20.1. Prevnar 13 14.20.2. Synflorix 14.20.3. Pneumovax 23 14.21. India Pneumonia Vaccine Market Forecast, By Distribution Channel 14.21.1. Distribution Partner Companies 14.21.2. Non-governmental Organizations (NGO) 14.21.3. Government Authorities 14.22. Japan Pneumonia Vaccine Market Forecast, By Vaccine Type 14.22.1. Pneumococcal Conjugate Vaccine 14.22.2. Pneumococcal Polysaccharide Vaccine 14.23. Japan Pneumonia Vaccine Market Forecast, By Sector 14.23.1. Public 14.23.2. Private 14.24. Japan Pneumonia Vaccine Market Forecast, By Product Type 14.24.1. Prevnar 13 14.24.2. Synflorix 14.24.3. Pneumovax 23 14.25. Japan Pneumonia Vaccine Market Forecast, By Distribution Channel 14.25.1. Distribution Partner Companies 14.25.2. Non-governmental Organizations (NGO) 14.25.3. Government Authorities 14.26. ASEAN Pneumonia Vaccine Market Forecast, By Vaccine Type 14.26.1. Pneumococcal Conjugate Vaccine 14.26.2. Pneumococcal Polysaccharide Vaccine 14.27. ASEAN Pneumonia Vaccine Market Forecast, By Sector 14.27.1. Public 14.27.2. Private 14.28. ASEAN Pneumonia Vaccine Market Forecast, By Product Type 14.28.1. Prevnar 13 14.28.2. Synflorix 14.28.3. Pneumovax 23 14.29. ASEAN Pneumonia Vaccine Market Forecast, By Distribution Channel 14.29.1. Distribution Partner Companies 14.29.2. Non-governmental Organizations (NGO) 14.29.3. Government Authorities 14.30. Rest of Asia Pacific Pneumonia Vaccine Market Forecast, By Vaccine Type 14.30.1. Pneumococcal Conjugate Vaccine 14.30.2. Pneumococcal Polysaccharide Vaccine 14.31. Rest of Asia Pacific Pneumonia Vaccine Market Forecast, By Sector 14.31.1. Public 14.31.2. Private 14.32. Rest of Asia Pacific Pneumonia Vaccine Market Forecast, By Product Type 14.32.1. Prevnar 13 14.32.2. Synflorix 14.32.3. Pneumovax 23 14.33. Rest of Asia Pacific Pneumonia Vaccine Market Forecast, By Distribution Channel 14.33.1. Distribution Partner Companies 14.33.2. Non-governmental Organizations (NGO) 14.33.3. Government Authorities 14.34. Asia Pacific Pneumonia Vaccine Market Attractiveness Analysis 14.34.1. By Vaccine Type 14.34.2. By Sector 14.34.3. By Product Type 14.34.4. By Distribution Channel 14.35. PEST Analysis 14.36. Key Trends 14.37. Key Developments 15. Middle East & Africa Pneumonia Vaccine Market Analysis 15.1. Key Findings 15.2. Middle East & Africa Pneumonia Vaccine Market Overview 15.3. Middle East & Africa Pneumonia Vaccine Market Value Share Analysis, By Vaccine Type 15.4. Middle East & Africa Pneumonia Vaccine Market Forecast, By Vaccine Type 15.4.1. Pneumococcal Conjugate Vaccine 15.4.2. Pneumococcal Polysaccharide Vaccine 15.5. Middle East & Africa Pneumonia Vaccine Market Value Share Analysis, By Sector 15.6. Middle East & Africa Pneumonia Vaccine Market Forecast, By Sector 15.6.1. Public 15.6.2. Private 15.7. Middle East & Africa Pneumonia Vaccine Market Value Share Analysis, By Product Type 15.8. Middle East & Africa Pneumonia Vaccine Market Forecast, By Product Type 15.8.1. Prevnar 13 15.8.2. Synflorix 15.8.3. Pneumovax 23 15.9. Middle East & Africa Pneumonia Vaccine Market Value Share Analysis, By Distribution Channel 15.10. Middle East & Africa Pneumonia Vaccine Market Forecast, By Distribution Channel 15.10.1. Distribution Partner Companies 15.10.2. Non-governmental Organizations (NGO) 15.10.3. Government Authorities 15.11. Middle East & Africa Pneumonia Vaccine Market Value Share Analysis, by Country 15.12. Middle East & Africa Pneumonia Vaccine Market Forecast, by Country 15.12.1. GCC 15.12.2. South Africa 15.12.3. Rest of Middle East & Africa 15.13. Middle East & Africa Pneumonia Vaccine Market Analysis, by Country 15.14. GCC Pneumonia Vaccine Market Forecast, By Vaccine Type 15.14.1. Pneumococcal Conjugate Vaccine 15.14.2. Pneumococcal Polysaccharide Vaccine 15.15. GCC Pneumonia Vaccine Market Forecast, By Sector 15.15.1. Public 15.15.2. Private 15.16. GCC Pneumonia Vaccine Market Forecast, By Product Type 15.16.1. Prevnar 13 15.16.2. Synflorix 15.16.3. Pneumovax 23 15.17. GCC Pneumonia Vaccine Market Forecast, By Distribution Channel 15.17.1. Distribution Partner Companies 15.17.2. Non-governmental Organizations (NGO) 15.17.3. Government Authorities 15.18. South Africa Pneumonia Vaccine Market Forecast, By Vaccine Type 15.18.1. Pneumococcal Conjugate Vaccine 15.18.2. Pneumococcal Polysaccharide Vaccine 15.19. South Africa Pneumonia Vaccine Market Forecast, By Sector 15.19.1. Public 15.19.2. Private 15.20. South Africa Pneumonia Vaccine Market Forecast, By Product Type 15.20.1. Prevnar 13 15.20.2. Synflorix 15.20.3. Pneumovax 23 15.21. South Africa Pneumonia Vaccine Market Forecast, By Distribution Channel 15.21.1. Distribution Partner Companies 15.21.2. Non-governmental Organizations (NGO) 15.21.3. Government Authorities 15.22. Rest of Middle East & Africa Pneumonia Vaccine Market Forecast, By Vaccine Type 15.22.1. Pneumococcal Conjugate Vaccine 15.22.2. Pneumococcal Polysaccharide Vaccine 15.23. Rest of Middle East & Africa Pneumonia Vaccine Market Forecast, By Sector 15.23.1. Public 15.23.2. Private 15.24. Rest of Middle East & Africa Pneumonia Vaccine Market Forecast, By Product Type 15.24.1. Prevnar 13 15.24.2. Synflorix 15.24.3. Pneumovax 23 15.25. Rest of Middle East & Africa Pneumonia Vaccine Market Forecast, By Distribution Channel 15.25.1. Distribution Partner Companies 15.25.2. Non-governmental Organizations (NGO) 15.25.3. Government Authorities 15.26. Middle East & Africa Pneumonia Vaccine Market Attractiveness Analysis 15.26.1. By Vaccine Type 15.26.2. By Sector 15.26.3. By Product Type 15.26.4. By Distribution Channel 15.27. PEST Analysis 15.28. Key Trends 15.29. Key Developments 16. South America Pneumonia Vaccine Market Analysis 16.1. Key Findings 16.2. South America Pneumonia Vaccine Market Overview 16.3. South America Pneumonia Vaccine Market Value Share Analysis, By Vaccine Type 16.4. South America Pneumonia Vaccine Market Forecast, By Vaccine Type 16.4.1. Pneumococcal Conjugate Vaccine 16.4.2. Pneumococcal Polysaccharide Vaccine 16.5. South America Pneumonia Vaccine Market Value Share Analysis, By Sector 16.6. South America Pneumonia Vaccine Market Forecast, By Sector 16.6.1. Public 16.6.2. Private 16.7. South America Pneumonia Vaccine Market Value Share Analysis, By Product Type 16.8. South America Pneumonia Vaccine Market Forecast, By Product Type 16.8.1. Prevnar 13 16.8.2. Synflorix 16.8.3. Pneumovax 23 16.9. South America Pneumonia Vaccine Market Value Share Analysis, By Distribution Channel 16.10. South America Pneumonia Vaccine Market Forecast, By Distribution Channel 16.10.1. Distribution Partner Companies 16.10.2. Non-governmental Organizations (NGO) 16.10.3. Government Authorities 16.11. South America Pneumonia Vaccine Market Value Share Analysis, by Country 16.12. South America Pneumonia Vaccine Market Forecast, by Country 16.12.1. Brazil 16.12.2. Mexico 16.12.3. Rest of South America 16.13. South America Pneumonia Vaccine Market Analysis, by Country 16.14. Brazil Pneumonia Vaccine Market Forecast, By Vaccine Type 16.14.1. Pneumococcal Conjugate Vaccine 16.14.2. Pneumococcal Polysaccharide Vaccine 16.15. Brazil Pneumonia Vaccine Market Forecast, By Sector 16.15.1. Public 16.15.2. Private 16.16. Brazil Pneumonia Vaccine Market Forecast, By Product Type 16.16.1. Prevnar 13 16.16.2. Synflorix 16.16.3. Pneumovax 23 16.17. Brazil Pneumonia Vaccine Market Forecast, By Distribution Channel 16.17.1. Distribution Partner Companies 16.17.2. Non-governmental Organizations (NGO) 16.17.3. Government Authorities 16.18. Mexico Pneumonia Vaccine Market Forecast, By Vaccine Type 16.18.1. Pneumococcal Conjugate Vaccine 16.18.2. Pneumococcal Polysaccharide Vaccine 16.19. Mexico Pneumonia Vaccine Market Forecast, By Sector 16.19.1. Public 16.19.2. Private 16.20. Mexico Pneumonia Vaccine Market Forecast, By Product Type 16.20.1. Prevnar 13 16.20.2. Synflorix 16.20.3. Pneumovax 23 16.21. Mexico Pneumonia Vaccine Market Forecast, By Distribution Channel 16.21.1. Distribution Partner Companies 16.21.2. Non-governmental Organizations (NGO) 16.21.3. Government Authorities 16.22. Rest of South America Pneumonia Vaccine Market Forecast, By Vaccine Type 16.22.1. Pneumococcal Conjugate Vaccine 16.22.2. Pneumococcal Polysaccharide Vaccine 16.23. Rest of South America Pneumonia Vaccine Market Forecast, By Sector 16.23.1. Public 16.23.2. Private 16.24. Rest of South America Pneumonia Vaccine Market Forecast, By Product Type 16.24.1. Prevnar 13 16.24.2. Synflorix 16.24.3. Pneumovax 23 16.25. Rest of South America Pneumonia Vaccine Market Forecast, By Distribution Channel 16.25.1. Distribution Partner Companies 16.25.2. Non-governmental Organizations (NGO) 16.25.3. Government Authorities 16.26. South America Pneumonia Vaccine Market Attractiveness Analysis 16.26.1. By Vaccine Type 16.26.2. By Sector 16.26.3. By Product Type 16.26.4. By Distribution Channel 16.27. PEST Analysis 16.28. Key Trends 16.29. Key Developments 17. Company Profiles 17.1. Market Share Analysis, by Company 17.2. Competition Matrix 17.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 17.2.2. New Product Launches and Product Enhancements 17.2.3. Market Consolidation 17.2.3.1. M&A by Regions, Investment and Applications 17.2.3.2. M&A Key Players, Forward Integration and Backward Integration 17.3. Company Profiles: Key Players 17.3.1. Bayer AG 17.3.1.1. Company Overview 17.3.1.2. Financial Overview 17.3.1.3. Product Portfolio 17.3.1.4. Business Strategy 17.3.1.5. Recent Developments 17.3.1.6. Company Footprint 17.3.2. GlaxoSmithKline plc 17.3.3. Pfizer Inc. 17.3.4. Nuron Biotech Inc. 17.3.5. CSL Ltd. 17.3.6. Biomed Pvt. Ltd. 17.3.7. Serum Institute of India Pvt. Ltd. 17.3.8. Sanofi Pasteur Inc. 17.3.9. JN-International Medical Corporation 17.3.10. Merck & Co., Inc. 17.3.11. LG Chem Ltd. 17.3.12. Panacea Biotec Limited 17.3.13. Pnuvax Incorporated 17.3.14. Shenzhen Kangtai Biological Products Co., Ltd. 17.3.15. SK Bioscience 17.3.16. Walvax Biotechnology Co., Ltd. 18. Primary Key Insights